The exercise period for exercising the warrants of series TO4 begins today, Monday May 17, 2021
Today, Monday may 17, 2021, begins the exercise period for the exercising of the warrants of series TO4, that were issued in conjunction with Cyxone AB (publ)’s (”Cyxone” or ”the Company”) directed issue of units during the fourth quarter of 2020. In conjunction with the exercise periods beginning, Cyxone also publishes a letter to the warrant holders, including words from the CEO and instructions for how to exercise the warrants. The exercise price has been set to SEK 3.24 per new share and if all warrants are exercised, the Company will receive approximately SEK 19.5 million before issuing costs. The exercise period will continue up to and including May 28, 2021. Note that some nominees may close the exercise period earlier than May 28, 2021.
Summarized terms for the warrants of series TO4:
Exercise period: May 17, 2021 – May 28, 2021.
Issue size: 6,003,157 warrants of series TO4, which entitles to subscription of 6,003,157 shares. If all the warrants are exercised, the Company will receive approximately SEK 19.5 million before issuing costs.
Last day of trading warrants of series TO4: May 21, 2021.
Dilution etc.: If all warrants are exercised the share capital will increase with approximately SEK 453,068.70, from SEK 4,382,145.83 to SEK 4,835,214.53. If all warrants are exercised the number of shares will increase with 6,003,157 shares, from 58,063,400 shares, to 64,066,557 shares. The dilution at the exercise of all warrants amounts to approximately 9.37 percent of the number of shares and votes.
The letter to the holders of warrants of series TO4 and the complete terms for the warrants are attached to this press release and will be available on the Company’s website, www.cyxone.com.
Note that the warrants that are not exercised at the latest May 28, 2021, or sold at the latest May 21, 2021, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.
How warrants are exercised:
Nominee-registered warrants (Custody account)
Subscription and payment by the exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.
Direct-registered warrants (Securities account)
No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form.
The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.
Mangold Fondkommission AB is the financial adviser and Fredersen Advokatbyrå AB is the legal adviser for Cyxone regarding the warrants.
For questions regarding the warrants, please contact:
Mangold Fondkommission AB
Tel: +46 8 5050 1595
Tara Heitner, CEO
Tel: +46 70 781 88 08
211 22 Malmö, Sweden
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, firstname.lastname@example.org. For more information, please visit www.cyxone.com.